# Novel Drug Approvals at FDA

## Novel Drug Approvals for 2023

1. **Izervay**: Approved on August 4, 2023, Izervay, which contains avacincaptad pegol, is indicated for the treatment of geographic atrophy secondary to age-related macular degeneration.

2. **Brenzavvy**: On January 20, 2023, Brenzavvy, with the active ingredient bexagliflozin, was approved to improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise.

3. **Bimzelx**: Approved on October 17, 2023, Bimzelx, containing bimekizumab, is used to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

4. **Filsuvez**: Filsuvez, with the active ingredient birch triterpenes, was approved on December 18, 2023, for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa.

5. **Truqap**: Approved on November 16, 2023, Truqap, containing capivasertib, is indicated for the treatment of breast cancer that meets certain disease criteria.

6. **Pombiliti**: Pombiliti, with the active ingredient cipaglucosidase alfa-atga, was approved on September 28, 2023, to treat late-onset Pompe disease.

7. **Jesduvroq**: On February 1, 2023, Jesduvroq, containing daprodustat, was approved for the treatment of anemia caused by chronic kidney disease for adults on dialysis for at least four months.
